baricitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	5202	1187594-09-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: baricitinib LY3009104 INCB028050 olumiant	Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulates these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs. FDA issued an Emergency use authorization (EUA) on November 19, 2020 that permits use of baricitinib in combination with remdesivir for treatment of suspected or laboratory-confirmed COVID-19 in hospitalized patients ≥2 years of age requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Molecular weight: 371.42 Formula: C16H17N7O2S CLOGP: 0.48 LIPINSKI: 0 HAC: 9 HDO: 1 TPSA: 120.56 ALOGS: -3.02 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

baricitinib
LY3009104
INCB028050
olumiant

Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulates these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs. FDA issued an Emergency use authorization (EUA) on November 19, 2020 that permits use of baricitinib in combination with remdesivir for treatment of suspected or laboratory-confirmed COVID-19 in hospitalized patients ≥2 years of age requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Molecular weight: 371.42
Formula: C16H17N7O2S
CLOGP: 0.48
LIPINSKI: 0
HAC: 9
HDO: 1
TPSA: 120.56
ALOGS: -3.02
ROTB: 4

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	mg	O

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.04 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company
Feb. 13, 2017	EMA	Eli Lilly Nederland B.V.
May 31, 2018	FDA	ELI LILLY AND CO
July 3, 2017	PMDA	Eli Lilly Japan KK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Therapy interrupted	201.14	19.45	81	4981	32374	63451586
COVID-19	113.03	19.45	84	4978	113019	63370941
Thrombocytosis	71.23	19.45	24	5038	5794	63478166
Deep vein thrombosis	69.98	19.45	56	5006	83744	63400216
Pulmonary embolism	57.68	19.45	58	5004	116626	63367334
COVID-19 pneumonia	56.66	19.45	26	5036	14183	63469777
Therapy cessation	50.46	19.45	31	5031	30426	63453534
Fibrin D dimer increased	43.39	19.45	16	5046	5018	63478942
Sputum culture positive	43.36	19.45	13	5049	2154	63481806
Tooth dislocation	39.88	19.45	6	5056	30	63483930
Herpes zoster	37.11	19.45	39	5023	82423	63401537
Leukopenia	35.58	19.45	37	5025	77253	63406707
Illness	35.10	19.45	30	5032	49029	63434931
Ovarian adenoma	32.55	19.45	7	5055	303	63483657
Cervicobrachial syndrome	29.14	19.45	8	5054	969	63482991
Transaminases increased	28.38	19.45	22	5040	31345	63452615
Herpes simplex reactivation	28.34	19.45	7	5055	561	63483399
Pneumonia haemophilus	27.14	19.45	7	5055	668	63483292
Ultrasound Doppler abnormal	24.81	19.45	5	5057	157	63483803
Pneumonia bacterial	24.77	19.45	13	5049	9452	63474508
Diverticulitis	23.92	19.45	22	5040	39535	63444425
Tubular breast carcinoma	23.65	19.45	4	5058	46	63483914
Sudden death	23.57	19.45	13	5049	10436	63473524
Normochromic normocytic anaemia	23.36	19.45	10	5052	4626	63479334
Liver function test increased	23.33	19.45	20	5042	32791	63451169
Immunodeficiency common variable	22.81	19.45	5	5057	237	63483723
Lymph node tuberculosis	21.34	19.45	6	5056	793	63483167
Tumour necrosis factor receptor-associated periodic syndrome	21.30	19.45	4	5058	86	63483874
Chondrocalcinosis	20.92	19.45	6	5056	852	63483108
Arthrodesis	20.86	19.45	8	5054	2793	63481167
Foeticide	19.94	19.45	3	5059	15	63483945
Inflammatory marker increased	19.65	19.45	10	5052	6829	63477131

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary embolism	223.36	31.75	117	2571	89629	34864614
Deep vein thrombosis	170.39	31.75	88	2600	65160	34889083
Off label use	103.01	31.75	142	2546	419382	34534861
Pneumonia bacterial	55.47	31.75	24	2664	11848	34942395
COVID-19 pneumonia	53.21	31.75	26	2662	16941	34937302
Fibrin D dimer increased	46.65	31.75	16	2672	4228	34950015
Bronchopulmonary aspergillosis	44.58	31.75	22	2666	14637	34939606
Immobilisation syndrome	44.16	31.75	9	2679	311	34953932
Pneumothorax spontaneous	38.30	31.75	9	2679	606	34953637
Acute respiratory failure	36.29	31.75	25	2663	30903	34923340
Liver function test increased	35.97	31.75	19	2669	14546	34939697
COVID-19	34.86	31.75	36	2652	77514	34876729
Alanine aminotransferase increased	33.62	31.75	36	2652	80779	34873464
Solar urticaria	33.09	31.75	5	2683	27	34954216

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Therapy interrupted	256.54	18.55	97	6574	31244	79706473
Pulmonary embolism	222.43	18.55	152	6519	171502	79566215
Deep vein thrombosis	195.35	18.55	123	6548	120796	79616921
COVID-19 pneumonia	95.11	18.55	47	6624	28802	79708915
COVID-19	94.54	18.55	89	6582	157585	79580132
Fibrin D dimer increased	90.04	18.55	32	6639	8622	79729095
Therapy cessation	78.05	18.55	45	6626	37517	79700200
Pneumonia bacterial	74.32	18.55	35	6636	19296	79718421
Sputum culture positive	63.28	18.55	20	6651	3761	79733956
Leukopenia	58.98	18.55	60	6611	116453	79621264
Off label use	56.64	18.55	185	6486	907030	78830687
Herpes zoster	54.67	18.55	52	6619	93031	79644686
Liver function test increased	50.77	18.55	35	6636	39738	79697979
Illness	45.85	18.55	35	6636	46476	79691241
Bronchopulmonary aspergillosis	41.80	18.55	25	6646	22269	79715448
Tooth dislocation	39.76	18.55	6	6665	29	79737688
Leukocytosis	34.91	18.55	29	6642	43426	79694291
Thrombocytosis	34.50	18.55	16	6655	8510	79729207
Alanine aminotransferase increased	34.19	18.55	54	6617	162516	79575201
Ovarian adenoma	33.86	18.55	7	6664	238	79737479
Diverticulitis intestinal perforated	33.47	18.55	7	6664	252	79737465
Acute respiratory failure	32.56	18.55	32	6639	59509	79678208
Respiratory failure	32.53	18.55	56	6615	180855	79556862
PaO2/FiO2 ratio decreased	31.81	18.55	5	6666	33	79737684
Pneumothorax spontaneous	29.86	18.55	9	6662	1445	79736272
Lung adenocarcinoma	29.48	18.55	14	6657	7850	79729867
Herpes simplex reactivation	29.19	18.55	7	6664	472	79737245
Pneumonia staphylococcal	29.00	18.55	12	6659	4862	79732855
Pneumomediastinum	28.69	18.55	11	6660	3656	79734061
Blood culture positive	28.56	18.55	14	6657	8415	79729302
Aspartate aminotransferase increased	27.69	18.55	45	6626	138596	79599121
Staphylococcal infection	27.62	18.55	29	6642	58266	79679451
Pneumonia pseudomonal	26.77	18.55	12	6659	5899	79731818
Solar urticaria	26.37	18.55	5	6666	108	79737609
Drug ineffective for unapproved indication	25.19	18.55	26	6645	51212	79686505
Ultrasound Doppler abnormal	24.60	18.55	5	6666	156	79737561
Pneumonia haemophilus	22.98	18.55	7	6664	1165	79736552
Pneumocystis jirovecii pneumonia	22.65	18.55	20	6651	32488	79705229
Toxicity to various agents	22.63	18.55	4	6667	421536	79316181
Arthrodesis	21.66	18.55	8	6663	2399	79735318
Lymphocyte count decreased	21.47	18.55	23	6648	47266	79690451
Infection	21.36	18.55	56	6615	241656	79496061
Tumour necrosis factor receptor-associated periodic syndrome	21.11	18.55	4	6667	86	79737631
Acute respiratory distress syndrome	21.01	18.55	22	6649	44045	79693672
Post herpetic neuralgia	21.00	18.55	8	6663	2613	79735104
Legionella infection	20.97	18.55	6	6665	804	79736913
Hypoxia	19.92	18.55	33	6638	103210	79634507
Lymph node tuberculosis	19.64	18.55	6	6665	1008	79736709
Pulseless electrical activity	19.34	18.55	13	6658	14147	79723570

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AA37	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants
FDA MoA	N0000190857	Janus Kinase Inhibitors
FDA EPC	N0000190858	Janus Kinase Inhibitor
CHEBI has role	CHEBI:22587	antiviral agents
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:35842	anti-rheumatic drugs
CHEBI has role	CHEBI:67079	anti-inflammatory agents
CHEBI has role	CHEBI:76617	BTK inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atopic dermatitis	indication	24079001	DOID:3310
Alopecia areata	indication	68225006	DOID:986
Rheumatoid arthritis	indication	69896004	DOID:7148
Pneumonia caused by Severe acute respiratory syndrome coronavirus 2	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.49	acidic
pKa2	4.6	Basic
pKa3	1.9	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1MG	OLUMIANT	ELI LILLY AND CO	N207924	Oct. 8, 2019	RX	TABLET	ORAL	8420629	March 10, 2029	TREATMENT OF RHEUMATOID ARTHRITIS
2MG	OLUMIANT	ELI LILLY AND CO	N207924	May 31, 2018	RX	TABLET	ORAL	8420629	March 10, 2029	TREATMENT OF RHEUMATOID ARTHRITIS
1MG	OLUMIANT	ELI LILLY AND CO	N207924	Oct. 8, 2019	RX	TABLET	ORAL	9737469	Nov. 2, 2031	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
2MG	OLUMIANT	ELI LILLY AND CO	N207924	May 31, 2018	RX	TABLET	ORAL	9737469	Nov. 2, 2031	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
4MG	OLUMIANT	ELI LILLY AND CO	N207924	May 10, 2022	RX	TABLET	ORAL	9737469	Nov. 2, 2031	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
1MG	OLUMIANT	ELI LILLY AND CO	N207924	Oct. 8, 2019	RX	TABLET	ORAL	11045474	Nov. 30, 2032	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
1MG	OLUMIANT	ELI LILLY AND CO	N207924	Oct. 8, 2019	RX	TABLET	ORAL	9089574	Nov. 30, 2032	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
2MG	OLUMIANT	ELI LILLY AND CO	N207924	May 31, 2018	RX	TABLET	ORAL	11045474	Nov. 30, 2032	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
2MG	OLUMIANT	ELI LILLY AND CO	N207924	May 31, 2018	RX	TABLET	ORAL	9089574	Nov. 30, 2032	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
4MG	OLUMIANT	ELI LILLY AND CO	N207924	May 10, 2022	RX	TABLET	ORAL	11045474	Nov. 30, 2032	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
4MG	OLUMIANT	ELI LILLY AND CO	N207924	May 10, 2022	RX	TABLET	ORAL	9089574	Nov. 30, 2032	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1MG	OLUMIANT	ELI LILLY AND CO	N207924	Oct. 8, 2019	RX	TABLET	ORAL	May 31, 2023	NEW CHEMICAL ENTITY
2MG	OLUMIANT	ELI LILLY AND CO	N207924	May 31, 2018	RX	TABLET	ORAL	May 31, 2023	NEW CHEMICAL ENTITY
4MG	OLUMIANT	ELI LILLY AND CO	N207924	May 10, 2022	RX	TABLET	ORAL	May 31, 2023	NEW CHEMICAL ENTITY
1MG	OLUMIANT	ELI LILLY AND CO	N207924	Oct. 8, 2019	RX	TABLET	ORAL	May 10, 2025	TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
2MG	OLUMIANT	ELI LILLY AND CO	N207924	May 31, 2018	RX	TABLET	ORAL	May 10, 2025	TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
4MG	OLUMIANT	ELI LILLY AND CO	N207924	May 10, 2022	RX	TABLET	ORAL	May 10, 2025	TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
1MG	OLUMIANT	ELI LILLY AND CO	N207924	Oct. 8, 2019	RX	TABLET	ORAL	June 13, 2025	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
2MG	OLUMIANT	ELI LILLY AND CO	N207924	May 31, 2018	RX	TABLET	ORAL	June 13, 2025	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
4MG	OLUMIANT	ELI LILLY AND CO	N207924	May 10, 2022	RX	TABLET	ORAL	June 13, 2025	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Tyrosine-protein kinase JAK1	Kinase	P23458	JAK1_HUMAN	INHIBITOR	IC50	8.23	SCIENTIFIC LITERATURE	DRUG LABEL
Tyrosine-protein kinase JAK2	Kinase	O60674	JAK2_HUMAN	INHIBITOR	IC50	8.24	SCIENTIFIC LITERATURE	DRUG LABEL
Rho-associated protein kinase 1	Kinase	Q13464	ROCK1_HUMAN		Kd	6.32	CHEMBL
Protein kinase C beta type	Kinase	P05771	KPCB_HUMAN		Kd	4.58	CHEMBL
Protein kinase C delta type	Kinase	Q05655	KPCD_HUMAN		Kd	5.97	CHEMBL
Rho-associated protein kinase 2	Kinase	O75116	ROCK2_HUMAN		Kd	6.12	CHEMBL
Protein kinase C alpha type	Kinase	P17252	KPCA_HUMAN		Kd	5.68	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta	Kinase	Q13557	KCC2D_HUMAN		Kd	6.51	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Kinase	Q13555	KCC2G_HUMAN		Kd	6.61	CHEMBL
AP2-associated protein kinase 1	Kinase	Q2M2I8	AAK1_HUMAN	INHIBITOR	Kd	7.77	IUPHAR
Serine/threonine-protein kinase MARK2	Kinase	Q7KZI7	MARK2_HUMAN		Kd	6.90	CHEMBL
Serine/threonine-protein kinase N1	Kinase	Q16512	PKN1_HUMAN		Kd	6.98	CHEMBL
BMP-2-inducible protein kinase	Kinase	Q9NSY1	BMP2K_HUMAN	INHIBITOR	Kd	7.40	IUPHAR
Dual specificity protein kinase CLK1	Kinase	P49759	CLK1_HUMAN		Kd	6.11	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN	INHIBITOR	Kd	6.87	IUPHAR
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		IC50	6.10	CHEMBL
Serine/threonine-protein kinase N2	Kinase	Q16513	PKN2_HUMAN		Kd	6.57	CHEMBL
Non-receptor tyrosine-protein kinase TNK1	Kinase	Q13470	TNK1_HUMAN		Kd	6.21	CHEMBL
Casein kinase I isoform gamma-2	Kinase	P78368	KC1G2_HUMAN		Kd	6.58	CHEMBL
cAMP-dependent protein kinase catalytic subunit alpha	Kinase	P17612	KAPCA_HUMAN		Kd	5.44	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.36	CHEMBL
Casein kinase I isoform gamma-1	Kinase	Q9HCP0	KC1G1_HUMAN		Kd	5.76	CHEMBL
Serine/threonine-protein kinase ULK1	Kinase	O75385	ULK1_HUMAN		Kd	6.09	CHEMBL
Mitogen-activated protein kinase kinase kinase 1	Kinase	Q13233	M3K1_HUMAN		Kd	5.72	CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 1	Kinase	Q9BQI3	E2AK1_HUMAN		Kd	6.47	CHEMBL
Uncharacterized protein FLJ45252	Unclassified	Q6ZSR9	YJ005_HUMAN		Kd	7.11	CHEMBL
Septin-9	Enzyme	Q9UHD8	SEPT9_HUMAN		Kd	7.08	CHEMBL
Non-receptor tyrosine-protein kinase TYK2	Kinase	P29597	TYK2_HUMAN	INHIBITOR	IC50	7.28	SCIENTIFIC LITERATURE
MAP/microtubule affinity-regulating kinase 3	Kinase	P27448	MARK3_HUMAN		Kd	6.98	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		Kd	6.01	CHEMBL

External reference:

ID	Source
ISP4442I3Y	UNII
4037600	VANDF
C4044947	UMLSCUI
CHEBI:95341	CHEBI
3JW	PDB_CHEM_ID
CHEMBL2105759	ChEMBL_ID
44205240	PUBCHEM_CID
DB11817	DRUGBANK_ID
D10308	KEGG_DRUG
9570	INN_ID
7792	IUPHAR_LIGAND_ID
256448	MMSL
32650	MMSL
354624	MMSL
d08568	MMSL
017220	NDDF
726518002	SNOMEDCT_US
763701005	SNOMEDCT_US
2047232	RXNORM
C000596027	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4182	TABLET, FILM COATED	2 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4182	TABLET, FILM COATED	2 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4182	TABLET, FILM COATED	2 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4182	TABLET, FILM COATED	2 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4479	TABLET, FILM COATED	4 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4479	TABLET, FILM COATED	4 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4479	TABLET, FILM COATED	4 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4732	TABLET, FILM COATED	1 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4732	TABLET, FILM COATED	1 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4732	TABLET, FILM COATED	1 mg	ORAL	NDA	34 sections
Olumiant	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4732	TABLET, FILM COATED	1 mg	ORAL	NDA	34 sections
Baricitinib	HUMAN PRESCRIPTION DRUG LABEL	1	0002-6885	TABLET, FILM COATED	4 mg	ORAL	Emergency Use Authorization	2 sections
Baricitinib	HUMAN PRESCRIPTION DRUG LABEL	1	0002-6885	TABLET, FILM COATED	4 mg	ORAL	Emergency Use Authorization	2 sections